Natural products remain an important source of new drugs. Many natural materials are used for treatment of diseases. The diversity in natural compounds make it a rich source for discovering and studying the biological activities for overcoming of several diseases. Cancer is a leading reason of death all over the world. Many anticancer agents originate from plant sources occupies an important position in anticancer studies. The advances happened in chemical and clinical tools encourage many of researcher to rediscover many natural compounds and plants could not be studied in past. This chapter reviews the natural products from plant sources with anticancer activity. It represents the most effective natural products with anticancer activity. Their structures and chemical classifications with the plant sources are presented. The article focuses on the promising natural products and the ongoing trails to evaluate the plant wealth as anticancer phytochemicals. The natural compounds in the advanced stages of clinical development is discussed.
IgnacimuthuS., AyyanarM. and SivaramanK.S., Ethnobotanical investigations among tribes in Madurai district of Tamil Nadu (India), Journal of Ethnobiology and Ethnomedicine2 (2006), 25–31.
2.
ElujobaA.A., OdeleyeM.O. and OgunyemiM.C., Traditional medicine development for medical and dental primary health care delivery system in Africa, African Journal of Traditional, Complementary and Alternative Medicines2 (2005), 46–61.
3.
GordonC.M. and DavidJ., Plants as a source of anti-cancer agents, Journal of Ethnopharmacology100 (2005), 72–79.
4.
KingstonD.G.I. and NewmanJ.D., Mother Nature’s combinatorial libraries: Their influence on the synthesis of drugs, Current opinion in drug discovery & development5 (2002), 304–316.
5.
ShuY.Z., Recent natural products based drug development: A pharmaceutical industry perspective, Journal of Natural Products61 (1998), 1053–1071.
6.
NewmanJ.D., CraggM.G. and SnaderM.K., Natural products as sources of new drugs over the period 1981–2002, Journal of Natural Products66 (2003), 1022–1037.
7.
NewmanJ.D., CraggM.G. and SnaderM.K., The influence of natural products upon drug discovery, Natural Products Reports17 (2000), 215–234.
8.
HenkelT., BrunneM.R., MullerH. and RechelF., Statistical investigation into the structural complementarity of natural products and synthetic compounds, Angewandte Chemie- International Edition38 (1999), 643–647.
9.
HailN.Jr, Mitochondria: A novel target for the chemoprevention of cancer, Apoptosis10 (2005), 687–705.
10.
AggarwalB.B., DandaD., GuptaS. and GehlotP., Models for prevention and treatment of cancer: Problems vs promises, Biochemical Pharmacology78 (2009), 1083–1094.
11.
MadhuriS. and PandeyG., Some dietary agricultural plants with anticancer properties, Plant Archives8 (2008), 13–16.
12.
BasmadjianC., ZhaoQ., BentouhamiE., DjehalA., NebigilG.C., JohnsonA.R., SerovaM., de GramontA.,
FaivreS.,
RaymondE. and DésaubryL.G., Cancer wars: Natural products strike back, Frontiers in Chemistry2 (2014), 1–20.
13.
TulpM. and BohlinL., Functional versus chemical diversity: Is biodiversity important for drug discovery?Trends in Pharmacological Sciences23 (2002), 225–231.
14.
NewmanJ.D. and CraggM.G., Natural products as sources of new drugs over the last 25 years, Natural Products70 (2007), 461–477.
15.
SchaufelbergerD., KoleckM., BeutlerJ., VatakisA., AlvaradoA., AndrewsP., MarzoL., MuschikG., RoachJ., RossJ., LebherzW., ReevesM., EberweinR., RodgersL., TestermanR., SnaderK. and ForenzaS., The large scale isolation of Bryostatin 1 from Bugula neritina following good manufacturing practices, Journal of Natural Products54 (1991), 1265–1270.
16.
FabricantS.D. and FarnsworthR.N., The value ofplants used in traditional medicine for drug discovery, Environmental Health Perspectives109 (2001), 69–75.
17.
RaskinI., RibnickyM.D., KomarnytskyS., IlicN., PoulevA., BorisjukN., BrinkerA., MorenoD.A., RipollC., YakobyN., O’NealJ.M., CornwellT., PastorI. and FridlenderB., Plants and human health in the twenty-first century, Trends Biotechnology20 (2002), 522–531.
18.
FarnsworthR.N., AkereleO. and BingelS.A., Bulletin of the World Health Organization, Medicinal Plants in Therapy63 (1985), 965–981.
19.
NirmalaJ.M., SamundeeswariA.A. and SankarD.P., Natural plant resources in anti-cancer therapy- A review, Research in Plant Biology1 (2011), 1–14.
20.
WallE.M. and WaniC.M., Camtothecin: Discovery to clinic. Annals of the New York Academy of Sciences803 (1996), 1–12.
21.
WaniC.M., TaylorL.H., WallE.M., CoggonP. and McPhailT.A., The Isolation and Structure of Taxol, a Novel Antileukemic and Antitumor Agent from Taxus brevifolia, Journal of American Chemical Society93 (1971), 2325–2327.
22.
ShuZ.Y., Recent Natural Products Based Drug Development: A Pharmaceutical Industry Perspective, Journal of Natural Products61 (1998), 1053–1071.
23.
ZaidH., SilbermannM., Ben-AryeE. and SaadB., Greco-Arab and Islamic herbal-derived Anticancer Modalities: From tradition to molecular mechanisms, Evidence-based Complementary and Alternative Medicine2012 (2012), 1–13.
24.
WenT., JinjianL., MingqingH., YingboL., MeiwanC., GuoshengW., JianG., ZhangfengZ., ZengtaoX., YuanyeD., JiajieG., XiupingC. and YitaoW., Anti-cancer natural products isolated from chinese medicinal herbs, Chinese Medicine6 (2011), 1–15.
25.
CraggM.G. and NewmanJ.D., Plants as a source of anti-cancer agents, Journal of Ethnopharmacology100 (2005), 72–79.
26.
GeethangiliM., RaoK.Y., FangH.S. and TzengM.Y., Cytotoxic constituents from Andrographis paniculata induce cell cycle arrest in jurkat cells, Phytotherapy Research22 (2008), 1336–1341.
27.
KumarA.R., SrideviK., KumarN.V., NanduriS. and RajagopalS., Anticancer and immunostimulatory compounds from Andrographis paniculata, Journal of Ethnopharmacology92 (2004), 291–295.
28.
MurielM.J., Herbs or Natural Products That Decrease Cancer Growth, Oncology Nursing Forum31 (2004), 75–90.
29.
KumariP., MisraK., SisodiaS.B., FaridiU., SrivastavaS., LuqmanS., DarokarP.M., NegiS.A., GuptaM.M., SinghC.S. and KumarK.J., A promising anticancer and antimalarial component from the leaves of Bidens pilosa, Planta Medica5 (2009), 59–61.
30.
SundararajanP., DeyA., SmithA., DossG.A., RajappanM. and NatarajanS., Studies of anticancer and antipyretic activity of Bidens pilosa whole plant, Africa Health Sciences6 (2006), 27–30.
31.
GuangC.Y.Z., XiangZ.H.F.T., WeiC.D., DaG.K. and XiW.L., Tubeimoside V (1), a new cyclic bisdesmoside from tubers of Bolbostemma paniculatum, functions by inducing apoptosis in human glioblastoma U87MG cells, Bioorganic & Medicinal Chemistry Letters16 (2006), 4575–4580.
32.
YuL., MaR., WangY. and NishinoH., Potent anti-tumor activity and low toxicity of tubeimoside 1 isolated from Bolbostemma paniculatum, Bolbostemma paniculatum, Planta Medica60 (1994), 204–208.
33.
Galve-RoperhI., SanchezC., CortesM.L., PulgarT.G., IzquierdoM. and GuzmanM., Anti-tumoral action of cannabinoids: Involvement of sustained ceramide accumulation and extracullar signal-regulated kinase activation, Nature Medicine6 (2000), 313–319.
KupchanS.M. and BaxterL.R., Mezerein: Anti leukemicrinciple isolated from Daphne mezereum. Life Science187 (1975), 652–653.
36.
ZhenS.H., Study of anticancer effect in vivo of active fraction from Nervillia fordii, Zhong Yao Cai30 (2007), 1095–1098.
37.
NizamutdinovaT.I., LeeW.G., LeeS.J., ChoK.M., SonH.K. and JeonJ.S., Tanshinone -I suppresses growth and invasion of human breast cancer cells, MDA- MB- 231, through regulation of adhesion molecules, Carcinogenesis29 (2008), 1885–1892.
38.
YoonY., KimY., JeonK.W., ParkJ.H. and SunJ.H., Tanshinone IIA isolated from Salvia miltiorrhiza B. induced apoptosis in HL60 human premyelocytic leukemia cell line, Journal of Ethno Pharmacology68 (1999), 121–127.
39.
AroraS., KawK. and KaurS., Indian Medicinal Plants as reserver of protective phytochemicals, Tetragenesis, Carcinogenesis and Mutagenesis23 (2003), 295–300.
40.
SaleemM., HushumM., HarkonenP. and PihlajaK., Inhibition of cancer cell growth by crude extract andphenolics of Terminalia chebula fruit, Journal of Ethnopharmacology81 (2002), 327–336.
41.
BhoomikaR., RameshG.K. and AnitaM.A., Phyto-pharmacology of Achyranthes aspera: A Review, Pharmacognosy Reviews1 (2007), 143–150.
42.
ChakrabortyA., BrantnerT., MukainakaY., NobukuniM., KuchideT., KonoshimaH., TokudaH. and NishinoH., Cancer chemopreventive activity of Achyranthes aspera leaves on Epstein-Barr virus activation and two-stage mouse skin carcinogenesis, Cancer letters177 (2002), 1–5.
43.
NajjarE.I.N., Anti-colon cancer effects of Salograviolide A isolated from Centaurea ainetensis, Centaurea ainetensis, Oncology Reports19 (2008), 897–904.
44.
GhantousA., TayyounA.A., LteifG.A., SalibaA.N., Gali-MuhtasibG., El-SabbanM. and DarwicheN., Purified salograviolide A isolated from Centaurea ainetensis causes growth inhibition and apoptosis in neoplastic epidermal cells, International Journal of Oncology32 (2008), 841–849.
45.
FredericoP., RafaelD.C., DaltonJ.D., MiriamT.P.L. and NadiaB.R., Antioxidant and cytotoxic activities of Centell asiatica, International Journal of Molecular Science10 (2009), 3713–3721.
46.
HuangH.Y., ZhangH.S., ZhenR., XuX.D. and ZhenS.Y., Asiaticoside inducing apoptosis of tumour cells and enhancing antitumour activity of vincristin, Ai Zheng23 (2004), 1599–1604.
47.
ParkC.B., BosireO.K., LeeS.E., LeeS.Y. and KimA.J., Asiatic acid induced apoptosis in SK-MEL-2 human melanoma cells, Cancer Letters218 (2005), 81–90.
48.
AlecuM., UrsaciucC. and HalalauF., Photodynamic treatment of basal cell carcinoma and squamous cell carcinoma with hypericin, Anticancer Research18 (1988), 4651–4654.
49.
WadaA., SakaedaT., TakaraK., HiraiM., KimuraT., OhmotoN., ZhouJ., NakamuraT., KobayashiH., OkamuraN., YagamiT. and OkumuraK., Effects of St John’s wort and hypericin on cytotoxicity of anticancer drugs, Drug Metabolism & Pharmacokinetics17 (2002), 467–474.
50.
RoyK.M., NakaharaK., NaV.T., TrakoontivakornG., TakenakaM., IsobeS. and TsushidaT., Baicalein, a flavonoid extracted from a methanolic extract of Oroxylum indicum inhibits proliferation of a cancer cell line in vitro via induction of apoptosis, Pharmazie62 (2007), 149–153.
51.
KumarA.R., RajkumarV., GuhaG. and MatheL., Therapeutic Potentials of Oroxylum indicum Bark Extracts, Chinese Journal of Natural Medicines8 (2010), 121–126.
52.
JennaK.J., JoyK.L. and KuttanR., Effect of Emblica officinalis, Phyllanthus amarus and Picrorrhiza kurroa on N-Nitrosodiethylamine induced hepatocardinogenesis, Cancer Letters136 (1999), 11–16.
53.
MoritaH., YamamiyaT., TakeyaK. and ItokawaH., New antitumour bicyclic hexapeptides, RA-IX, XII, XIII and XIV from Rubia cordifolia, Chemical and Pharmaceutical Bulletin40 (1992), 1352–1354.
54.
MoritaH., YamamiyaT. and TakeyaK., Conformational Recognition of RA–XII by 80S ribosomes: A different line broadening study in 1H NMR spectroscopy, Chemical and Pharmaceutical Bulletin41 (1993), 781–783.
55.
GuptaP.P., SrimalC.R., VermaN. and TandonS.J., Biological Activity of Rubia cordifolia and Isolation of an Active Principle, Pharmaceutical Biology37 (1999), 46–49.
56.
ParajuliP., JosheeN., RimandoM.A., MittalS. and YadavS.K., In vitro antitumor mechanisms of various Scutellaria extracts and constituent flavonoids, Planta Medica75 (2009), 41–48.
57.
AgarwalR., AgarwalC., IchikawaH., SinghR.P. and AgarwalB.B., Anticancer potential of silymarin: From bench to bed side. Anticancer Research26 (2006), 4457–4498.
58.
LiL.Y., GanP.G., ZhangZ.H., WuZ.H., LiL.C. and HuangP.Y., A flavonoid glycoside isolated from Smilax china L. rhizome in vitro anticancer effects on human cancer cell lines, Journal of Ethnopharmacology113 (2007), 115–124.
59.
XuW., LiuJ., LiC., WuZ.H. and LiuW.Y., Kaempferol-7-O-beta-D-glucoside (KG) isolated from Smilax china L. rhizome induces G2/M phase arrest and apoptosis on HeLa cells in a p53- independent manner, Cancer Letters264 (2008), 229–240.
60.
LiL.Y., GanP.G., ZhangZ.H., WuZ.H., LiL.C., HuangP.Y., LiuW.Y. and LiuW.J., A flavonoid glycoside isolated from Smilax china L. rhizome in vitro anticancer effects on human cancer cell lines, Journal of Ethnolpharmacology113 (2007), 115–124.
61.
XuD.K., WuY., WeiL.D., FangY.Z., XiaoL.Y., XiaoZ.C., ZiZ.C. and BaoC.C., The anti-tumor effects of alkaloids from the seeds of Strychnos nux-vomica on HepG2 cells and its possible mechanism, Journal of Ethnopharmacology106 (2006), 179–186.
62.
RaoS.P., RamanadhamM. and PrasadN.M., Anti-proliferative effects of Syrychnos nux-vomica root extract on human multiple myeloma cell line- RPMI 8226, Food & Chemical Toxicology47 (2009), 283–288.
63.
SigstedtC.S., Evaluation of aqueous extracts of Taraxacum officinale on growth and invasion of breast and prostate cancer cells, International Journal of Oncology32 (2008), 1085–1090.
64.
HyunN.K., SeungH.H., BongS.K., CheorlK.H., YoungY.H. and HyungK.M., Taraxacum officinale induces cytotoxicity through TNF-α and IL-1α secretion in Hep G2 cells, Life Sciences74 (2004), 1149–1157.
65.
LeciaG.J., JetaimeR. and ErnestI.B., Vernonia amygdalina: Anticancer activity, Authentication, and Adultration detection, International Journal of Environment Research: Public Health5 (2008), 342–348.
66.
AliM. and ShuaibM., Withanolides from the stem bark of Withania somnifera, Phytochemistry44 (1997), 1163–1168.
67.
ChakrabortiS.K., DeK.B. and BandyopadhyayT., Variations in the Antitumor Constituents of Withania somnifera, Experientia30 (1974), 852–872.
68.
JayaprakasamB., ZhangY., SeeramN. and NairM., Growth inhibition of tumor cell lines by withanolides from Withania somnifera leaves, Life Sciences74 (2003), 125–152.
69.
ChoedonT., MathanG., AryaS., KumarL.V. and KumarV., Anticancer and cytotoxic properties of the latex of Calotropis procera in a transgenic mouse model of hepatocellular carcinoma world journal of Gastroenterology, 12 (2006), 2517–2522.
70.
SmitF.H., WoerdenbagJ.H., SinghH.R., MeulenbeldJ.G., LabadieP.R. and ZwavingH.J., Ayurvedic herbal drugs with possible cytostatic activity, Journal of Ethnopharmacology47 (1995), 75–84.
71.
HamedI.A., PlazaA., BalestrieriL.M., MahalelA.U., SpringuelV.I., OleszekW., PizzaC. and PiacenteS., Cardenolide glycosides from Pergularia tomentosa and their proapoptotic activity in Kaposi’s sarcoma cells, Journal of Natural Products69 (2006), 1319–1322.
72.
RoyC.M., ChangR.F., HuangC.H., ChiangY.M. and WuC.Y., Cytotoxic principles from the formosan milkweed, Asclepias curassavica, Journal of Natural Products68 (2005), 1494–1499.
73.
ItokawaH., IbraheimZ.Z., YaQ.F. and TakeyaK., Anthraquinones, naphthohydroquinones and naphthohydroquinone dimmers from Rubia cordifolia and their cytotoxic activity, Chemical and Pharmaceutical Bulletin41 (1993), 1869–1872.
JianB., ZhangH., HanC. and LiuJ., Anti-Cancer Activities of Diterpenoids Derived from Euphorbia fischeriana Steud, Molecules23 (2018), 1–11.
76.
MadhuriL. and PandeyG., Some anticancer medicinal plants of foreign Origin, Current Science96 (2009), 779–783.
77.
DesaiG.A., Medicinal plants and cancer chemoprevention, Current Drug Metabolism9 (2008), 581–591.
78.
MohammadS., Anticancer agents from medicinal plants, Bangladesh Journal of Pharmacology1 (2006), 35–41.
79.
BhutaniK.K. and GohilV.M., Natural product drug discovery research in India: Status & appraisal, Indian Journal of Experimental Biology48 (2010), 199–207.
80.
LemkebL.T., WilliamsA.D., RocheF.V., WilliamS.Z., editors. Foye’s principles of medicinal chemistry. 6th ed. Philadelphia: Lippincott Williams & Wikins; 2008, 1147 pp. ISNB: 978-0-7817-6879-5.
81.
RajkapoorB., JayakarB. and MurugeshN., Antitumor activity of Indigofera aspalathoides on Ehrlisch ascites carcinoma in mice, Indian Journal of Pharmacology36 (2004), 38–40.
82.
BlockG., PattersonB. and SubarA., Fruit, vegetables, and cancer prevention: A review of the epidemiological evidence, Nutrition and Cancer18 (1992), 1–29.
83.
SteinmetzA.K. and PotterD.J., Vegetables, fruit, and cancer prevention: A review, Journal of the American Dietetic Association96 (1996), 1027–1039.
84.
AggarwalB.B. and ShishodiaS., Molecular targets of dietary agents for prevention and therapy of cancer, Biochemical Pharmacology71 (2006), 1397–1421.
85.
ScharfenbergK., WagnerR. and WagnerG.K., The cytotoxic effect of ajoene, a natural product from garlic, investigated with different cell lines, Cancer Letters53 (1990), 103–108.
86.
ThomsonM. and AliM., Garlic (Allium sativum): A review of its potential use as an anti-cancer agent, Current Cancer Drug Targets3 (2003), 67–81.
87.
BanasenthilS., RamachandranR.C. and NaginiS., Prevention of 4-nitroquinoline-1-oxide induced rat tongue carcinogenesis by garlic, Fitoterapia72 (2001), 524–531.
88.
BrownC.A., ShahC., LiuJ., PhamT.J., ZhangG.J. and JadusR.M., Ginger’s (Zingiber officinale Roscoe) inhibition of rat colonic adenocarcinoma cells proliferation and angiogenesis in vitro, Phototherapy Research23 (2009), 640–545.
89.
HoC.Y., YangF.S., PengY.C., ChouY.M. and ChangC.Y., Epigallocatechin-3-gallate inhibits the invasion of human oral cancer cells and decreases the productions of matrix etalloproteinases and urokinase-plasminogen activator, Journal of Oral Pathol Medicine36 (2007), 588–593.
90.
NishikawaT., NakajimaT., MoriguchiM., JoM., SekoguchiS., IshiiM., TakashimaH., KatagishiT., KimuraH., MinamiM., ItohY., KagawaK. and OkanoueT., A green tea polyphenol, epigalocatechin-3-gallate, induces apoptosis of human hepatocellular carcinoma, possibly through inhibition of Bcl-2 family proteins, Journal of Hepatology44 (2006), 1074–1082.
91.
SpinellaF., RosanoL., DecandiaS., DiV.C., AlbiniA., EliaG., NataliG.P. and BagnatoA., Antitumor effect of green tea polyphenol epigallocatechin-3-gallate in ovarian carcinoma cells: Evidence for the endothelin-1 as a potential target, Experimental Biology and Medicine231 (2006), 1123–1127.
92.
SpinellaF., RosanoL., DiV.C., DecandiaS., AlbiniA., NicotraR.M., NataliG.P. and BagnatoA., Green tea polyphenol epigallocatechin-3-gallate inhibits the endothelin axis and downstream signaling pathways in ovarian carcinoma, Molecular Cancer Therapeutics5 (2006), 1483–1492.
93.
HwangT.J., HaJ., ParkJ.I., LeeK.S., BaikW.H., KimM.Y. and ParkJ.O., Apoptotic effect of EGCG in HT-29 colon cancer cells via AMPK signal pathway, Cancer Letters247 (2007), 115–121.
94.
PengG., DixonA.D., MugaJ.S., SmithJ.T. and WargovichJ.M., Green tea polyphenol (-)-epigallocatechin-3-gallate inhibits cyclooxygenase-2 expression in colon carcinogenesis, Molecular Carcinogenesis45 (2006), 309–319.
95.
HuZ., YangY., HoC.P., ChanY.S., HengW.P., ChanE., DuanW., KohL.H. and ZhouS., Herb-drug interactions: A literature review, Drugs65 (2005), 1239–1282.
96.
Garrido-GarridoG., Martinez-SanchezG., Pardo-AndreuG., Garcia-RiveraD., Hernandez-CasanaP., Rodeiro-GuerraI., Guevara-GarciaM., Delgado-HernandezR. and Nunez-SellesA.J., Recent advances in the research & development of an aqueous stem bark extract obtained from Mangifera indica L, Recent Developments in Medicinal Plant Research9 (2007), 169–192.
97.
NunezA., CastroH., AgueroJ.A., GonzalezJ., NaddeoF., DeF.S. and RastrelliL., Isolation and quantitative analysis of phenolic antioxidants, free sugars and polyphenols from Mango (Mangifera indica L.) stem bark aqueous decoction used in Cuba as a nutritional supplement, Journal of Agriculture Food Chemistry50 (2002), 762–766.
98.
KunnumakkaraB.A., AnandP. and AggarwalB.B., Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins, Cancer Letters269 (2008), 199–225.
99.
StewardW.P. and GescherJ.A., Curcumin in cancer management: Recent results of analogue design and clinical studies and desirable future research, Molecular Nutrition & Food Research52 (2008), 1005–1009.
100.
KamatM.A., SethiG. and AggarwalB.B., Curcumin potentiates the apoptotic effects of chemotherapeutic agents and cytokines through down-regulation of nuclear factor-kappaB and nuclear factor-kappaB-regulated gene products in IFN-alpha-sensitive and IFN-alpha-resistant human bladder cancer cells, Molecular Cancer Therapeutics6 (2007), 1022–1030.
101.
JangM., CaiL., UdeaniO.G., SlowingV.K., ThomasF.C., BeecherW.C., FongH.H., FarnsworthR.N., KinghornD.A., MehtaG.R., MoonR.C. and PezzutoM.J., Cancer chemopreventive activity of resveratrol, a natural product derived from grapes, Science275 (1997), 218–220.
102.
AdhamiM.V., AfaqF. and AhmadN., Suppression of ultraviolet B exposure-mediated activation of NF-kappaB in normal human keratinocytes by resveratrol, Neoplasia5 (2003), 74–82.
103.
ZhangS., HunterJ.D., FormanR.M., RosnerA.B., SpeizerE.F., ColditzA.G., MansonE.J., HankinsonS.E. and WillettC.W., Dietary carotenoids and vitamins A, C, and E and risk of breast cancer, Journal of National Cancer Institute91 (1999), 547–556.
104.
DahanK., FennalM. and KumarB.N., Lycopene in the prevention of prostate cancer, Journal of the Society for Integrative Oncology6 (2008), 29–36.
105.
LensM. and MedenicaL., Systemic retinoids in chemoprevention of non-melanoma skin cancer, Expert Opinion on Pharmacotherapy9 (2008), 1363–1374.
106.
ChauhanD., LiG., PodarK., HideshimaT., NeriP., HeD., MitsiadesN., RichardsonP., ChangY., SchindlerJ., CarverB. and AndersonC.K., A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells, Cancer Research65 (2005), 8350–8358.
107.
HoyokuN., MichiakiM., HarukuniT. and YoshikoS., Cancer prevention by carotenoids, Archives of Biochemistry and Biophysics483 (2009), 165–168.
108.
Xu-yingaW., MingaL., Xiao-dongL. and PingH., Hepatoprotective and anti-hepatocarcinogenic effects of glycyrrhizin and matrine, Chemico-Biological Interactions181 (2009), 15–19.
109.
LiangC., McCleanD.M., MarsitC., ChristensenB., PetersE., NelsonH.H. and KelseyT.K., A Population-Based Case-Control Study of Marijuana Use and Head and Neck Squamous Cell Carcinoma, Cancer Prevention Research2 (2009), 759–768.
110.
Shiu-ChenH., Chi-TangH., Shoei-YnL. and Jen-KunL., Carnosol inhibits the invasion of B16/F10 mouse melanoma cells by suppressing metalloproteinase-9 through down-regulating nuclear factor-kappa B and c-Jun, Biochemical Pharmacology69 (2005), 221–232.
111.
LiM., ZhangZ., HillL.D., ChenX., WangH. and ZhangR., Genistein, a dietary isoflavone, down-regulates the MDM2 oncogene at both transcriptional and posttranslational levels, Cancer Research65 (2005), 8200–8208.
112.
RuizD., EgeaJ. and Tomas-BarberanF.A., Gil MI Carotenoids from new apricot (Prunus armeniaca L.) varieties and their relationship with flesh and skin color, Journal of Agricultural Food Chemistry53 (2005), 6368–6374.
113.
KimY.G., KimH.J., AhnC.S., LeeJ.H., MoonO.D., LeeM.C. and ParkM.Y., Lycopene suppresses the lipopolysaccharide-induced phenotypic and functional maturation of murine dendritic cells through inhibition of mitogen-activated protein kinases and nuclear factor-kappaB, Immunology1132 (2004), 203–211.
114.
SunilaS.E. and KuttanG., Immunomodulatory and antitumor activity of Piper longum Linn. and piperine, Journal of Ethnopharmacology90 (2004), 339–346.
115.
ShishodiaS., MajumdarS., BanerjeeS. and AggarwalB.B., Ursolic acid inhibits nuclear factor-kappaB activation induced by carcinogenic agents through suppression of IkappaBalpha kinase and p65 phosphorylation: Correlation with downregulation of cyclooxygenase 2, matrix metalloproteinase 9, and cyclin D1, Cancer Research63 (2003), 4375–4383.
116.
TakadaY. and AggarwalB.B., Betulinic acid suppresses carcinogen-induced NF-kappa B activation through inhibition of I kappa B alpha kinase and p65 phosphorylation: Abrogation of cyclooxygenase-2 and matrix metalloprotease-9, Journal of Immunology171 (2003), 3278–3286.
117.
ChengH.Y., ShenF.T., PangF.V. and ChenJ.B., Effects of aflatoxin and carotenoids on growth performance and immune response in mule ducklings, Comparative Biochemistry Physiology Toxicology Pharmacollogy128 (2001), 19–26.
118.
AbdullaevI.F., Cancer chemopreventive and tumoricidal properties of saffron (Crocus sativus L.), Experimental Biology and Medicine227 (2002), 20–25.
119.
KohnoH., MardaM. and HonjoS., Prevention of colonic preneoplastic lesions by the beta-cryptoxanthine and hesperidine rich powder prepared from Citrus Unshiu Marc, Juice in male F344 rats, Journal of Toxicologic Pathology12 (1999), 209–215.
120.
HanS.S., KeumS.Y., SeoJ.H., ChunS.K., LeeS.S. and SurhJ.Y., Capsaicin suppresses phorbol ester-induced activation of NF-kappaB/Rel and AP-1 transcription factors in mouse epidermis, Cancer Letters164 (2001), 119–126.
121.
YangF., OzS.H., BarveS.,
de VilliersWJ,
McClainJ.C. and VarilekW.G., The green tea polyphenol (-)-epigallocatechin-3-gallate blocks nuclear factor-kappa B activation by inhibiting I kappa B kinase activity in the intestinal epithelial cell line IEC-6, Molecular Pharmacology60 (2001), 528–533.
122.
MannaK.S., MukhopadhyayA. and AggarwalB.B., Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-kappaB, activator protein-1, and apoptosis: Potential role of reactive oxygen intermediates and lipid peroxidation, Journal of Immunology164 (2000), 6509–6519.
123.
ChengH.Y., ShenF.T., PangF.V. and ChenJ.B., Effects of aflatoxin and carotenoids on growth performance and immune response in mule ducklings, Comparative Biochemistry Physiology Toxicology Pharmacollogy128 (2001), 19–26.
124.
BerkardaB., KoyuncuH., SoybirT.G. and BaykutF., Inhibitory effect of hesperidin on tumor initiation and promotion in mouse skin, Research in Experimental Medicine198 (1998), 93–99.
125.
LaughtonJ.M., EvansJ.P., MoroneyA.M., HoultR.J. and HalliwellB., Inhibition of mammalian 5-lipoxygenase and cyclooxygenase by flavonoids and phenolic dietary additives. Relationship to antioxidant activity and to iron ionreducing ability, Biochemical Pharmacology42 (1991), 1673–1681.
126.
SolimanF.K. and MazzioA.E., In vitro attenuation of nitric oxide production in C6 astrocyte cell culture by various dietary compounds, Proceedings Society for Experimental Biology and Medicine218 (1998), 390–397.
127.
KumarA., DhawanS. and AggarwalB.B., Emodin (3-methyl-1,6,8-trihydroxyanthraquinone) inhibits TNF-induced NFkappaB activation, IkappaB degradation, and expression of cell surface adhesion proteins in human vascular endothelial cells, Oncogene17 (1998), 913–918.
128.
GengZ., RongY. and LauH.B., S-Allyl cysteine inhibits activation of nuclear factor kappa B in human T cells, Free Radic Biology Medicine23 (1997), 345–350.
129.
SueokaN., SueokaE., OkabeS. and FujikiH., Anti-cancer effects of morphine through inhibition of tumour necrosis factor-α release and mRNA expression, Carcinogenesis17 (1996), 2337–2341.
130.
KuneA.G., BannermanS., FieldB., WatsonF.L., ClelandH., MerensteinD. and VitettaL., Diet, smoking, serum beta-carotene and vitamin A in male nonmelanocytic skin cancer patients and controls, Nutrition and Cancer18 (1992), 237–244.
131.
GogateS.S., Cytotoxicity of neem leaf extract: An antitumor, National Medical Journal of India9 (1991), 297–304.
132.
BakerT.J., BorrisP.R., Carte'B., CordellA.G., SoejartoD.D., CraggM.G., GuptaP.M., IwuM.M., MadulidR.D. and TylerE.V., Natural products drug discovery and development: New perspectives on international collaboration, Journal of Natural Products58 (1995), 1325–1357.
133.
LeyV.S. and BaxendaleR.I., New tools and concepts for modern organic synthesis, Nature Reviews Drug Discovery1 (2002), 573–586.
134.
GeysenM.H., SchoenenF., WagnerD. and WagnerR., Combinatorial compound libraries for drug discovery: An ongoing challenge, Nature Reviews Drug Discovery2 (2003), 222–230.
135.
LombardinoG.J. and Lowe IIIJ.A., The role of the medicinal chemist in drug discovery-then and now, Nature Reviews Drug Discovery3 (2004), 853–862.
136.
ButlerS.M., The role of natural product chemistry in drug discovery, Journal of Natural Products67 (2004), 2141–2153.
137.
OrtholandY.J.>and
GanesanA, Natural products and combinatorial chemistry: Back to the future, Current Opinion in Chemical Biology8 (2004), 271–280.
138.
ButlerS.M., Natural products to drugs: Natural product-derived compounds in clinical trials, Journal of Natural Products25 (2008), 475–516.
139.
HarveyL.A., Natural products in drug discovery, Drug Discovery Today13 (2008), 894–901.
140.
HarveyL.A., Medicines from nature: Are natural products still relevant to drug discovery, Trends Pharmacological Sciences20 (1999), 196–198.
141.
RowinskyK.E., OnettoN., CanettaM.R. and ArbuckG.S., Taxol the 1st of the texanes, an important new class of antitumor agents, Seminars in Oncology19 (1992), 646–662.
142.
CreemersJ.G., BolisG., GoreM., ScarfoneG., LacaveJ.A., GuastallaP.J., DespaxR., FavalliG., KreinbergR., VanBelleS., HudsonI., VerweijJ. and HuininkW.W.T., Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: Results of a large European phase II study, Journal of Clinical Oncology14 (1996), 3056–3061.
143.
BertinoR.J., Irinotecan for colorectal cancer, Seminars in Oncology24 (1997), S18–S23.
144.
KantarjianM.H., O’BrienS., AnderliniP. and TalpazM., Treatment of chronic myelogenous leukemia: Current status and investigational options, Blood87 (1996), 3069–3081.
145.
LüS. and WangJ., Homoharringtonine and omacetaxine for myeloid hematological malignancies, Journal of Hematology & Oncology7 (2014), 1–10.
146.
ButlerS.M., The role of natural product chemistry in drug discovery, Journal of Natural Products67 (2004), 2141–2153.
147.
ReichertM.J., Trends in development and approval times for new therapeutics in the United States, Nature Reviews Drug Discovery2 (2003), 695–702.
148.
DicksonM. and GagnonP.J., Key factors in the rising cost of new drug discovery and development, Nature Reviews Drug Discovery3 (2004), 417–429.
149.
GlishL.G. and VachetW.R., The basics of mass spectrometry in the twenty-first century, Nature Reviews Drug Discovery2 (2003), 140–150.
150.
BlundellL.T., JhotiH. and AbellC., High-throughput crystallography for lead discovery in drug design, Nature Reviews Drug Discovery1 (2002), 45–54.
151.
KoehnE.F. and CarterT.G., The evolving role of natural products in drug discovery, Nature Reviews Drug Discovery4 (2005), 206–220.
